拜玛林制药 BMRN 深 沪
等待开盘 10-14 09:30:00 美东时间
54.38
-1.010
-1.82%
华盛通- 最 高55.655
- 今 开55.30
- 成交量 266.17万股
- 最 低 53.93
- 昨 收 55.39
- 总市值 105.27亿
- 52周最高 70.98
- 市盈率 静 30.13
- 换手率 1.38%
- 52周最低 49.2592
- 委 比 -40.50%
- 总股本 1.94亿
- 历史最高 151.75
- 量 比 0.99
- 振 幅 3.11%
- 历史最低 23.735
- 每 手 1
- 风险率 4.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioMarin Appoints Cara Bauer as Chief People Officer
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNe...
10-06 04:05
BioMarin Pharmaceutical Presents New Efficacy Data On POMBILITI + OPFOLDA In Pompe Disease At 31st Annual Congress Of World Muscle Society; No New Safety Signals Identified
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease (LOPD) were presented at the 31st Annual Congress of the World Muscle Society (WMS), in Hiroshima, Japan...
10-02 23:01
BioMarin Grants Ascendis Global License, Secures Royalty Revenues
The latest update is out from BioMarin Pharmaceutical ( ($BMRN) ). On September...
10-01 04:52
Travere Therapeutics Appoints Bradley L. Campbell President, CEO, Effective Dec. 1, Succeeding Eric Dube
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former...
09-22 04:06
BioMarin ends VOXZOGO development for Noonan syndrome
BioMarin Pharmaceutical ( ($BMRN) ) just unveiled an announcement. On September...
09-15 20:58
BioMarin Pharmaceutical Adds Independent Director to Board
An update from BioMarin Pharmaceutical ( ($BMRN) ) is now available. On Septemb...
09-14 21:48
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.
09-10 18:36
美股夜盘 | Chime Financial大升10.18%，富达国民金融上升3.00%
Chime Financial大升10.18%；富达国民金融上升3.00%；MACOM Technology Solutions上升2.98%
09-09 10:01
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target
Martin Shkreli, known as Pharma Bro, said Ultragenyx Pharmaceutical (NASDAQ:RARE) is undervalued and a potential takeover target for rare-disease peers like BioMarin Pharmaceuticals (NASDAQ:BMRN) after a trial setback. He said "$RARE is very cheap" and urged BioMarin and other rare-disease companies...
09-04 00:17
